Tianda Pharmaceuticals (HKSE:00455) Additional Paid-In Capital : HK$364.7 Mil(As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is Tianda Pharmaceuticals Additional Paid-In Capital?

Tianda Pharmaceuticals's quarterly additional paid-in capital increased from Sep. 2022 (HK$0.0 Mil) to Jun. 2023 (HK$364.7 Mil) but then stayed the same from Jun. 2023 (HK$364.7 Mil) to Dec. 2023 (HK$364.7 Mil).

Tianda Pharmaceuticals's annual additional paid-in capital stayed the same from Mar. 2021 (HK$0.0 Mil) to Mar. 2022 (HK$0.0 Mil) but then increased from Mar. 2022 (HK$0.0 Mil) to Dec. 2023 (HK$364.7 Mil).

Tianda Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Tianda Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianda Pharmaceuticals Additional Paid-In Capital Chart

Tianda Pharmaceuticals Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

364.73

Tianda Pharmaceuticals Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Jun23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															-	-	-	364.73	364.73

Tianda Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Tianda Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Tianda Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Tianda Pharmaceuticals (HKSE:00455) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianda Pharmaceuticals Ltd (HKSE:00455) » Definitions » Additional Paid-In Capital

Traded in Other Exchanges

N/A

Address

CITIC Tower, No. 1 Tim Mei Avenue, Suites 2405-2410, 24th Floor, Central, Hong Kong, HKG

Website

https://www.tiandapharma.com

Tianda Pharmaceuticals Ltd is engaged in R&D, manufactures and sales of pharmaceutical, biotechnology and healthcare products. The group also engages in R&D of Chinese medicine and manufacture and sales of Chinese medicine products, and the provision of Chinese medical services. Its operating segments include Chinese medicine business; Medical and healthcare services; and Pharmaceuticals and medical technologies business. The company derives majority of the revenue from Pharmaceuticals and medical technologies business.

Executives

Tianda Group Limited	2101 Beneficial owner
Fang Wen Quan	2201 Interest of corporation controlled by you

Tianda Pharmaceuticals (HKSE:00455) Headlines

No Headlines